Thomas Bartl

Gynecogic Oncologist・Junior Faculty @MedUni_Wien ・Editorial Fellow @IJGConline

[ESGO @ESGO_society]

🗣️ ICYMI: This week we learned The International Journal of Gynecological Cancer’s impact factor rose to 4.7! 📈 Congratulations to Pedro Ramirez, the editor-in-chief and his great team of editors! 💐

The IJGC is a joint project of ESGO & IGCS 👉 https://t.co/9FtpQERe9A

[Thomas Bartl @thomasbartlMD]

The low incidence of mucinous ovarian cancer continues to hinder both clinical and translational research. Prognosis remains unchanged for decades—with no Phase III trials in sight. It's time to shift the paradigm and drive progress!

[IJGC @IJGConline]

#2025SpecialIssue Controversies in the management of mucinous #ovariantumors

🔎 https://t.co/XYSmuMXLbr

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @thomasbartlMD @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen

[IJGC @IJGConline]

🌟 #IJGCconversations 🌟

Our EIC, @pedroramirezMD, had an incredible discussion with the @IJGCfellows about the #2025SpecialIssue topic: Rare Gynecologic Cancers 🎙️💡

Don’t miss this insightful conversation on the latest research and advancements in the field! 🔬✨

🎧 https://t.co/GrlHyn5fcU

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @thomasbartlMD @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelisse

[Thomas Bartl @thomasbartlMD]

Visiting Eurogin 2025 with Elmar Joura, who has been at the forefront of HPV research for 25 years @EUROGINHPV @ESGO_society @MedUni_Wien #hpv #hpvvaccination

[Thomas Bartl @thomasbartlMD]

👟 ESGO Cancer Awareness Run: Check! Thank you all for your effort raising awareness for Gynecologic Cancers!
#esgo2025

[Thomas Bartl @thomasbartlMD]

🚩Every third physician treating gynecologic cancer patients lacks confidence in managing checkpoint inhibitor side effects, underscoring the need for more specialized training and stronger interdisciplinary collaboration. #gynonc #oncoalert @AgoAustria
https://t.co/vV1g8xwNwy

[IJGC @IJGConline]

@thomasbartlMD #EditorialFellow

[IJGC @IJGConline]

Excited to have @thomasbartlMD join the inaugural cohort of #IJGC #EditorialFellows for #2025! 🎉
Beginning his #ESGO Fellowship at the Medical University of #Vienna, Dr. Bartl brings incredible expertise and passion to the team!👥

@pedroramirezMD @HsuMd @JayrajAarthi @AndreFernandes2 @IGCSociety @ESGO_society @ENYGO_official @OncoAlert @IJGCfellows @GynMe4 @kfischermd @claritasantia @stephjeangill @MMontesinos_Alb @braunchristian1 @mattmarchettiMD @yates_elisemann @jhgelissen
@RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada

#IJGConline #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc

[IJGC Fellows @IJGCfellows]

A great work! Congratulations

[Manel Montesinos-Albert @MMontesinos_Alb]

Thank you so much for the warm welcome! I am very excited to contribute to impactful research, collaborate with such an inspiring group, and learn from the incredible IJGC community. I look forward to growing together and making a difference! #EditorialFellows #IJGC